SCHEDULE: Citadel Discloses 4.9% Stake in Pliant Therapeutics

Citadel entities and Kenneth Griffin have jointly disclosed a 4.9% beneficial ownership stake in Pliant Therapeutics, Inc. common stock.

Summary

• Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of Common Stock, par value $0.0001 per share, of PLIANT THERAPEUTICS, INC. (CUSIP: 729139105).
• Kenneth Griffin is deemed to beneficially own 3,037,695 Shares, representing 4.9% of the class outstanding.
• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 2,099,798 Shares, representing 3.4% of the class.
• Citadel Securities LLC beneficially owns 909,171 Shares, representing 1.5% of the class.
• Citadel Securities Group LP and Citadel Securities GP LLC each beneficially own 937,897 Shares, representing 1.5% of the class.
• All reported shares are held with shared voting and shared dispositive power; no reporting person holds sole voting or sole dispositive power.
• The percentages are based on 61,449,385 Shares outstanding as of November 1, 2025, according to the issuer's Form 10-Q filed on November 6, 2025.
• The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the disclosure of a significant stake by a prominent institutional investor like Citadel can indicate increased market interest and potential confidence in Pliant Therapeutics.

Positives

• The disclosure of a significant stake by a prominent institutional investor like Citadel may signal increased institutional interest or confidence in Pliant Therapeutics.
• The aggregate beneficial ownership by Citadel entities and Kenneth Griffin reaching 4.9% indicates a notable position in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are common in the biotechnology sector, where firms like Pliant Therapeutics often attract investment from large hedge funds and asset managers. Citadel's stake suggests active interest in the company's prospects, which is a typical pattern for firms with potential drug pipelines or significant R&D activities.

Stakeholder Impact

• Shareholders: May view the institutional investment by Citadel as a positive indicator, potentially leading to increased investor confidence and interest in the stock.

Key Dates

Keywords

Pliant Therapeutics, Citadel, Kenneth Griffin, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Biotechnology, PLRX